Genta said it received fast track designation for its advanced gastric cancer drug candidate tesetaxel from US FDA.
Following positive results from a Phase 2a trial, Genta is conducting a confirmatory Phase 2b trial as second line treatment in patients with advanced gastric cancer.
A dose-ranging and pharmacokinetic study of tesetaxel in combination with capecitabine has also been completed.
Genta has prepared a clinical protocol and trial design for a Phase 3 trial.
Genta plans to submit its Phase 3 trial data to the FDA in the second quarter of this year in order to get a Special Protocol Assessment (SPA).
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData